India biotech startups are facing funding and regulatory challenges in 2026 as founders highlight difficulties in raising capital and securing approvals in India, prompting some companies to consider moving abroad, according to India Today report published on April 11, 2026.
The issue has drawn attention after an investor shared details of a startup working on advanced cancer vaccines. The company built a large research team and secured global support. However, it struggled to access long-term funding within India.
At the same time, regulatory timelines remain a concern. Clinical trial approvals can take longer, which slows down research progress. Because of this, startups face delays in bringing innovation to market.
What changed in India Biotech startups ecosystem
A recent X post by an investor highlighted challenges faced by a biotech founder. The founder returned to India after training abroad and built a team of over 100 scientists.
However, the company struggled to raise funds and manage regulatory processes. As a result, it is considering shifting its legal base outside India. This reflects a broader issue affecting India biotech startups.
Why Biotech startups are leaving India
Funding remains a key concern. Investors often avoid long-term commitments of 7–10 years required for biotech research.
At the same time, regulatory approvals for clinical trials can take longer compared to countries like the US or China. Because of this, founders look for better conditions abroad. The trend explains why biotech startups are leaving India.
Impact on innovation and economy
India biotech startups contribute to research and healthcare innovation. However, relocation of companies affects ownership and economic value.
When startups move abroad, intellectual property and future returns also shift. This reduces India’s role in global deep science leadership. The trend impacts long-term innovation capacity in the country.
Supporting data and industry context
India represents about 20% of the global population. However, it contributes around 1.5% of global clinical trials.
This gap shows challenges in converting scientific talent into applied innovation. Experts link this to funding gaps and regulatory delays. The X post also noted that startups with global backing still face barriers in India.
